Literature DB >> 3123404

Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.

S Silagi1, R Dutkowski, A Schaefer.   

Abstract

Successful immunotherapy of early s.c. or i.p. (B16) melanoma in syngeneic C57BL/6 (B6) mice was achieved with s.c. peri-lesional injections (for s.c. tumors) or i.p. injections (for i.p. tumors) of recombinant human interleukin 2 (rIL-2) and recombinant murine interferon-gamma (rIFN-gamma). Over a 28-day period, rIL-2 and rIFN-gamma were injected 14 times. Results with this combination were additive with s.c. tumors and synergistic with i.p. tumors. Treatment with 6,250 U-25,000 U of rIL-2 and 2 micrograms of rIFN-gamma began 1-3 days after s.c. inoculation of melanoma. On day 50, 87% (72/83) of mice thus treated were completely free of tumor. None of the 78 control mice (tumor + buffer) survived. Of mice receiving either rIL-2 or rIFN-gamma alone, 59% (47/79) and 53% (44/83), respectively, were tumor-free. I.p. tumors were also eradicated by i.p. injections of rIL-2 (50,000 U) with rIFN-gamma (5, 10, and 15 micrograms) as judged by absence of tumor in 81% (21/26) of mice autopsied between days 45 and 65. No control mice survived, and only 17% (2/12) and 20% (6/30) given either rIL-2 or rIFN-gamma separately (i.p.) were tumor-free. Doses of rIFN-gamma from 1-4 micrograms were more beneficial in eliminating 1-day s.c. melanomas than were higher doses, and local s.c. treatment was far superior to distant or systemic treatment. Non-adherent peritoneal or splenic cells from mice bearing 6-day-old i.p. melanomas and treated with one or both lymphokines on days 3 and 4 were used in cytotoxicity assays in vitro. Significant cytotoxicity against cultured melanoma cells was displayed by cells harvested from lymphokine-treated mice, but there was no evidence of the synergism observed with combination treatment of i.p. tumors in vivo. rIFN-gamma inhibited proliferation of melanoma cells in vitro, whereas rIL-2 stimulated proliferation at 1,000 U/ml. Plating efficiency was increased by at least 30% by culture with 100 U or 1,000 U of rIL-2/ml and both concentrations neutralized the inhibitory effect of 0.05 ng/ml of IFN-gamma, but not of 0.5 or 5.0 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123404     DOI: 10.1002/ijc.2910410225

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells.

Authors:  A B Geldhof; J Van Ginderachter; P Vandersteen; G Raes; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

2.  In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.

Authors:  R K Puri; P Leland
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

3.  Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.

Authors:  Y Tomita; H Watanabe; H Kobayashi; T Nishiyama; S Tsuji; M Fujiwara; S Sato
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2.

Authors:  A L Rakhmilevich; R J North
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

5.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism.

Authors:  L M Zheng; D M Ojcius; F Garaud; C Roth; E Maxwell; Z Li; H Rong; J Chen; X Y Wang; J J Catino; I King
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

6.  Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.

Authors:  M Iigo; K Nishikata; Y Nakajima; M Moriyama
Journal:  Jpn J Cancer Res       Date:  1989-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.